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Abstract
The isolation of nontuberculous mycobacteria (NTM) from clinical specimens has become very frequent in the last years. Such organ-
isms are typically environmental and poorly pathogenic for humans; they can, however, be responsible for opportunistic diseases in sub-
jects presenting with various predisposing conditions. Pulmonary infections are responsible for the most frequent disease caused by
NTM, although the relevance of mycobacterioses involving other parts of the body is increasing. The risk of disseminated infections
characterizing immunocompromised patients is well known, and those numbers are steadily rising. The lymph nodes, cutis and soft tis-
sues, as well as bone and joints, are also important targets of NTM infection. The problems concerning the assessment of the clinical
signiﬁcance of NTM, along with a consideration of the more frequent NTM pathologies, are the major objectives of this review.
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Introduction
Nontuberculous mycobacteria (NTM), of which at present
more than 130 species are known, are typical environmental
organisms; they have been frequently isolated from water,
but also from soil, dust and plants. Contact with contami-
nated environments may occasionally be responsible for
infection in humans and animals, with the possibility of trans-
mission from human to human being practically excluded [1].
The large majority of NTM are not pathogenic for humans,
but almost all can behave as opportunists and thus be
responsible for disease in the presence of predisposing
conditions.
The different species are almost equally divided between
rapid growers (which develop visible colonies on solid media
within 7 days) and slow growers (which require longer incu-
bation times). Growth rate, as opposed to other phenotypic
characteristics (e.g. colony pigmentation), has clinically
important repercussions. Rapid and slow growers differ in
their antimicrobial susceptibility [2]; furthermore, slow grow-
ers are most often responsible for pulmonary and lymphon-
odal diseases, whereas rapid growers prevalently affect cutis,
bones and joints [3].
Pulmonary Infections
The lung can be easily affected by inhalation of aerosolized
mycobacteria and is by far the most frequent site of human
mycobacteriosis. Two clearly distinct pictures exist.
First, in HIV-negative patients, the disease is undistinguish-
able from tuberculosis and is characterized by a very slow
progression [4]. The manifestations range from absence of
symptoms to cavitary disease, and an X-ray may reveal ﬁbro-
sis, upper lobe cavitation, nodular or parenchymal opacity,
and pleural thickening. The population most affected is
elderly patients with predisposing pulmonary conditions (e.g.
silicosis, obstructive pulmonary disease, pneumoconiosis,
previous tuberculosis, bronchiectasis or cancer). The symp-
toms include cough, fever, weight loss, weakness and respira-
tory insufﬁciency [5].
Second, in AIDS, patients the radiographic picture is often
normal or may reveal mediastinal or hilar adenopathy, and
the progression is very rapid. The most frequent symptoms
are cough, fever and weight loss. The patients are predomi-
nantly severely immunocompromised and have a CD4 lym-
phocyte count lower than 100/lL. In recent years, the
widespread use of highly active anti-retroviral treatments
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(HAART), comprising efﬁcacious preventers of extreme
lymphocyte depletion, has drastically reduced the frequency
of mycobacterial pulmonary disease in HIV-positive patients.
The NTM most frequently responsible for disease belong
to the Mycobacterium avium complex (MAC) with its two
major species M. avium and Mycobacterium intracellulare [6].
The typical disease affects primarily elderly men with restric-
tive or obstructive pulmonary conditions, and presents a
clinical picture of localized chronic pneumonia. By contrast,
Lady Windermere syndrome affects elderly women without
predisposing pulmonary conditions, but often presenting ana-
tomic abnormalities of the chest [7].
In Europe, infections caused by Mycobacterium xenopi [8]
and, particularly in Scandinavian countries and in Great Britain,
those caused by Mycobacterium malmoense [9] are very
frequent, whereas, in the USA, infections caused by Mycobac-
terium kansasii are by far more prevalent [10].
It is common knowledge that patients afﬂicted with cystic
ﬁbrosis, a genetic disease, are highly susceptible to bacterial
infections of the chest. Recently, infections as a result of
NTM have increasingly been reported, with several species
[11], mainly Mycobacterium abscessus and closely-related spe-
cies, more frequently affecting children, and with members of
MAC being more frequently isolated from adults.
In lipoid pneumonia, which is a speciﬁc form of lung inﬂam-
mation that develops when lipids enter the bronchial tree, a
strong association with the isolation of mycobacteria, predom-
inantly comprising rapid growers [12], has been reported,
although a causal correlation has not been demonstrated.
Hypersensitivity pneumonitis is an occupational disease
very frequent among people using metal-working ﬂuids. The
isolation of various species of rapidly growing mycobacteria
from the aerosols produced in such factories has lead to the
hypothesis that mycobacteria, more likely than the ﬂuids
themselves, could be responsible for the hypersensitivity
[13]. Again, rapid growers, and in particular Mycobacterium
immunogenum, are the species most frequently involved.
As opposed to what happens in other parts of the body,
in many cases, the isolation of an NTM from the respiratory
tract poses a problem rather than providing a solution. The
risk of contamination of the sputum by environmental myco-
bacteria is high and the mis-attribution of clinical signiﬁcance
to the ﬁnding would imply not only a useless treatment for
the patient, but also loss of sight of the real cause of disease.
No substantial agreement exists at present regarding colo-
nization, considered by some to be a nonpathogenic condi-
tion, and by others to be an early phase of disease [14]. A
correct assessment of the clinical signiﬁcance, which is esti-
mated to accompany no more than 30% of the isolations,
requires close collaboration between the clinician and the
microbiologist and, in some cases, the pathologist. The guide-
lines of the American Thoracic Society [15] (Table 1) pro-
vide strict criteria that apply in the presence of
pneumopathy, for which any cause other than NTM has been
excluded.
Important microbiological information concerns not only
the bacterial load and the number of isolations, but also
strain identiﬁcation. Several species are known to be more
prone than others to cause pulmonary disease; this is the
case of M. malmoense and Mycobacterium szulgai and, among
rapid growers, of M. abscessus. Furthermore, the role of
biopsy in cases in which granulomatous lesions with (but also
without) acid fast bacilli are detected is decisive.
Lymphonodal Infections
Lymphonodal infection as a result of NTM is typically an
infantile disease affecting, in most cases unilaterally, cervical
lymph nodes [16]. The route of infection is most likely the
mouth and the childhood habit of bringing hands and objects
to the mouth may well explain the particular susceptibility of
infants to this pathology. The size of neck swelling, which is
painless, varies considerably and ﬁstulization is not rare.
Antimicrobial treatment is generally ineffective, and healing
almost always requires surgical excision of the lymph nodes
involved [17]. The intervention, however, resolves the situa-
tion in no more than 80% of cases, with the remaining 20%
being characterized by relapse.
TABLE 1. Clinical and microbiological criteria for diagnos-
ing nontuberculous mycobacterial lung disease [15]
Clinical (both required)
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph,
or a high-resolution computed tomography scan that shows multifocal
bronchiectasis with multiple small nodules
and
2. Appropriate exclusion of other diagnoses
Microbiological
1. Positive culture results from at least two separate expectorated sputum
samples; if the results from one are nondiagnostic, repeating sputum smears
and cultures should be considered
or
2. Positive culture result from at least one bronchial wash or lavage
or
3. Transbronchial or other lung biopsy with mycobacterial histopathological
features (granulomatous inﬂammation or acid fast bacilli) and positive
culture for NTM or biopsy showing mycobacterial histopathological
features (granulomatous inﬂammation or acid fast bacilli) and one or
more sputum or bronchial washings that are culture positive for NTM
4. Expert consultation should be obtained when NTM are recovered that
are either infrequently encountered or that usually represent
environmental contamination
5. Patients who are suspected of having NTM lung disease but do not
meet the diagnostic criteria should be followed until the diagnosis is f
irmly established or excluded
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the
institution of therapy, which is a decision based on the potential risks and
beneﬁts of therapy for individual patients
NTM, nontuberculous mycobacteria.
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A major change in recent decades involves the aetiology
of cervical lymphadenitis; Mycobacterium scrofulaceum, previ-
ously considered the prevalent cause of the disease, became
quite rare, whereas M. avium is isolated more and more fre-
quently [18]. Interestingly, the incidence of lymphadenitis
caused by M. malmoense is growing also in countries other
than Scandinavia and the UK where this species is known to
be endemic. The number of isolations of recently-described
species from lymph nodes, among them Mycobacterium lent-
iﬂavum [19] and Mycobacterium bohemicum [20], is steadily
increasing as well as frequently reported.
A very peculiar kind of lymphadenitis, affecting both super-
ﬁcial and deep lymph nodes, develops in immunocompro-
mised patients, particularly during immune system
restoration that follows treatment with HAART. The dis-
ease, known as inmmunoreconstitution syndrome [21], is a
paradoxical reaction of the lymphatic system to a pre-exist-
ing, undiagnosed mycobacterial infection.
Cutis and Soft Tissues Infections
NTM infections of cutis and soft tissues (hand, elbow, knee
and foot being the main sites) are characterized by granuloma-
tous lesions developing a few weeks after infection. Satellite
lymph nodes also may be affected and evolution to ulceration
and cellulitis, and even to cutaneous dissemination, is not rare.
The most common sources include contact with contaminated
water or infected ﬁsh, traumas and surgical wounds.
The cutaneous infection caused by Mycobacterium marinum,
which mostly affects those who own aquariums and other
people in contact with ﬁsh, is the best known. The lesion,
usually at the hand or the forearm, is initially nodular but
may subsequently ulcerate; the sporotrychoid form is charac-
terized by small nodules along lymphatic ducts [22]. Sponta-
neous healing of the lesion is very rare. Mycobacterium
marinum is a photochromogenic species with optimal growth
at 32C; when incubated at this temperature, mature colo-
nies develop in <2 weeks, whereas the standard incubation
at 37C may be responsible for growth failure. Clinical suspi-
cion is therefore a major prerequisite for a successful micro-
biological diagnosis.
Other ﬁsh-borne cutaneous lesions, mainly caused by
Mycobacterium fortuitum and Mycobacterium chelonae, have
also been reported.
Mycobacterium ulcerans is the aetiologic agent of Buruli
ulcer [23], the third most common mycobacterial disease
after tuberculosis and leprosy; it is particularly frequent in
Africa and Australia. Large necrotizing ulcers, characterized
by the presence of heavy loads of strongly cytotoxic,
extracellular, bacilli, develop in the extremities, mainly in
children. The lesions are painless and the disease is not fatal,
but the development of large scars is highly invaliding. The
most important treatment is surgical excision followed by
skin transplantation. Waters of lakes and rivers are thought
to be the natural reservoir of M. ulcerans. Growth in culture
requires incubation at temperatures lower than 32C and is
slow; most strains grow poorly in culture.
Mycobacterium haemophilum [24], also a psychrophile spe-
cies, may be responsible for painful soft tissue abscesses,
sometimes relapsing, in immunocompromised patients,
mainly organ transplanted, HIV-infected or lymphoma
patients. Infections caused by M. haemophilum often remain
undiagnosed because growth of the mycobacterium in cul-
ture requires, in addition to incubation at an unusual growth
temperature, media that is enriched with blood derivatives.
Many rapid growers are often involved in post-traumatic
or post-surgical infections; the species most frequently
reported include M. fortuitum, M. chelonae and M. abscessus,
but increasingly reported are cases caused by recently
described new species, such as Mycobacterium goodii [25] and
Mycobacterium massiliense [26].
Outbreaks of cutaneous mycobacterioses, almost always
attributable to rapid growers, are increasingly reported
worldwide. The infectious agent is accidentally introduced
into the host by injection (multidose vaccines, local anaes-
thetic) or because of the use of contaminated disinfectants,
mostly on the occasion of cosmetic interventions.
Bone and Joint Infections
Infections involving joints and bones often originate from
traumas (e.g. open fractures) or surgical interventions. The
joint functionality is often severely compromised and evolu-
tion to osteomyelitis is not rare. Articular rheumatism and
steroid treatment are major predisposing conditions. Anti-
microbial treatment is poorly effective when not combined
with surgical toilette.
A number of mycobacterial species have been repeatedly
reported to be involved: M. haemophilum, M. kansasii, MAC,
Mycobacterium asiaticum, Mycobacterium ﬂavescens, M. szulgai,
M. xenopi and, among the rapid growers, Mycobacterium ther-
moresistibile and M. goodii [25].
A not negligible portion of cases of spondylodiscitis have a
mycobacterial aetiology, with those attributable to NTM
being as frequent as those caused by Mycobacterium tuber-
culosis. Both rapidly and slowly growing species may be
involved; among the latter, M. xenopi is one of the leading
causes [27].
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Disseminated Infections
Disseminated mycobacterial infections develop almost always
in severely immunocompromised people; the best known are
those that affect HIV-infected patients.
The respiratory apparatus and the gastrointestinal tract
are the two major routes of infection. The main symptoms
and signs include high fever, diarrhoea, weight loss, abdomi-
nal pain, sweating, hiccups, aneamia, hepatomegalia and sple-
nomegalia. The progression of disease may be very rapid and
even fatal. Blood culture on media speciﬁc for mycobacteria
is the procedure of choice for the diagnosis of such dissemi-
nated infections.
Disseminated MAC was one of the ﬁrst opportunistic
infections detected in AIDS patients [28]; it has been esti-
mated to affect approximately 50% of subjects with CD4
lymphocyte counts less than 100/lL [6]. In such patients,
infections caused by M. avium are four-fold more frequent
than those dur to M. intracellulare, which is an unexpected
proportion given that, in HIV-negative people, the involve-
ment of the two species overlaps.
The number of NTM species reported as responsible for
disseminated infections in AIDS patients is large; among
them, Mycobacterium genavense, a species which remains fre-
quently undiagnosed because of its inability to grow on con-
ventional solid media, has been estimated to be involved in
no less than 10% of the cases attributable to MAC [29].
Mixed infections have also been reported [30].
Several species, among these MAC and M. genavense,
appear to share a priviledged involvement in AIDS-dissemi-
nated infections. Such relatedness still remains unexplained,
in particular for those species that are not very common in
the environment or poorly pathogenic.
Presently, disseminated NTM disease is quite rare in HIV-
infected patients [31]; the use of HAART allows the maintain-
ance of the level of CD4 lymphocytes clearly above the level
at risk for such infections and, when not possible because of
resistance of the HIV strains, a prophylactic treatment is sufﬁ-
cient in most cases to keep the risk under control. However,
the frequency of disseminated NTM infections remains on the
rise in therapeutically immunosuppressed patients [32] and in
those with genetic immunodeﬁciencies.
An important predisposing condition to disseminated
mycobacterial infections is the immunosuppression estab-
lished to prevent the rejection of transplanted organs. The
number of reports concerning kidney and bone marrow
transplantation is particularly high and many species are
involved. Among them, an important role appears to be
played by M. haemophilum [24].
Disseminated mycobacterial infections, which, although
not rare, remain in many cases undiagnosed, may develop
concomitantly with antiblastic therapies of cancer, in particu-
lar of hairy cell leukaemia and chronic myeloid leukaemia
[33]. They originate, in most cases, from infected catheters
and should be suspected when a patient remains febrile
despite negative blood cultures (performed in media not
dedicated to mycobacteria). Particular attention should be
paid, in the case of such patients, to avoid confusing myco-
bacteria unexpectedly grown on common media with con-
taminants, because of their coryneform aspect [34]. Once
the mycobacterial nature of the infection is acknowledged
and the contaminated catheter is removed, proper treatment
is, with high probability, successful.
Catheter-related sepsis, mainly as a result of rapidly grow-
ing mycobacteria, has also been reported in hemodialysis
patients [35] and in surgical patients, primarily following car-
diac operations.
In recent years, the administration of antibodies against
interferon (IFN)-c has become a frequent practice for the
treatment of many immunomediated inﬂammatory diseases.
A side effect of the impairment of macrophagic activation,
consequent to the biological therapy, is the increased predis-
position to mycobacterial infections. A number of cases,
mostly disseminated, have been reported, some of which do
not respond to treatment [36].
Among genetic immunodeﬁciencies, the most liable to dis-
seminated mycobacterial infections are idiopathic CD4 lymp-
hopenia [37], the mutations of IFN-c-speciﬁc receptors, and
the production of anti IFN-c antibodies.
Conclusions
Opposite attitudes may be presented by clinicians with
regard to NTMs. They are in fact considered harmless
organisms by some, and the cause of a difﬁcult-to-diagnose
disease by others.
The truth is, as always, halfway between the opposing atti-
tudes, and a correct diagnosis requires an unbiased clinical
evaluation of diagnostic data. An important contribution can
come from microbiology, provided that the organism is care-
fully identiﬁed and proper methodologies are adopted. An
approximate identiﬁcation may lead to the under- or over-
valuation of the role of an isolate, whereas, on the other
hand, the use of unsuitable media and/or cultural conditions
may be responsible for missing signiﬁcant pathogens. A Cor-
rect identiﬁcation is at the basis of a proper treatment
which, because of the unreliability of NTM susceptibility test-
ing, must necessarily be based on data from the literature
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and take into account the different susceptibility patterns
that characterize rapidly and slowly growing species. As
expected, collaboration of the clinician and the microbiolo-
gist is crucial.
Transparency Declaration
No funding was used for this study. No commercial rela-
tionship or conﬂict of interest is expected.
References
1. Falkinham JO III. Epidemiology of infection by nontuberculous myco-
bacteria. Clin Microbiol Rev 1996; 9: 177–215.
2. N.C.C.L.S. Susceptibility testing for mycobacteria, nocardiae and other aer-
obic actinomycetes; approved standard M24-A. Wayne, PA: NCCLS,
2003.
3. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the
new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16: 319–354.
4. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary
disease in patients without HIV infection. Chest 2004; 126: 566–581.
5. Piersimoni C, Scarparo C. Pulmonary infections associated with non-
tuberculous mycobacteria in immunocompetent patients. Lancet Infect
Dis 2008; 8: 323–334.
6. Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium
complex. Clin Microbiol Rev 1993; 6: 266–310.
7. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle
lobe bronchiectasis and Mycobacterium avium complex infection due
to voluntary cough suppression. Clin Infect Dis 2000; 30: 572–575.
8. Jenkins PA, Campbell IA. Pulmonary disease caused by Mycobacterium
xenopi in HIV-negative patients: ﬁve year follow-up of patients receiv-
ing standardised treatment. Respir Med 2003; 97: 439–444.
9. Henriques B, Hoffner SE, Petrini B et al. Infection with Mycobacterium
malmoense in Sweden. Report of 221 cases. Clin Infect Dis 1994; 18:
596–600.
10. Arend SM, Cerda DP, de Haas P et al. Pneumonia caused by Mycobac-
terium kansasii in a series of patients without recognised immune
defect. Clin Microbiol Infect 2004; 10: 738–748.
11. Grifﬁth DE. Emergence of nontuberculous mycobacteria as pathogens
in cystic ﬁbrosis. Am J Respir Crit Care Med 2003; 167: 810–812.
12. Cox EG, Heil SA, Kleiman MB. Lipoid pneumonia and Mycobacterium
smegmatis. Pediatr Infect Dis J 1994; 13: 414–415.
13. Beckett W, Kallay M, Sood A et al. Hypersensitivity pneumonitis
associated with environmental mycobacteria. Environ Health Perspect
2005; 113: 767–770.
14. Field SK, Cowie RL. Lung disease due to the more common nontu-
berculous mycobacteria. Chest 2006; 129: 1653–1672.
15. Grifﬁth DE, Aksamit T, Brown-Elliott BA et al. An ofﬁcial ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007; 165: 367–
416.
16. Hazra R, Robson CD, Perez-Atayde AR et al. Lymphadenitis due to
nontuberculous mycobacteria in children: presentation and response
to therapy. Clin Infect Dis 1999; 28: 123–129.
17. Linheboom JA, Kuiper EJ, Bruijnesteijn Van Coppenraet ES et al. Sur-
gical excision versus antibiotic treatment for nontuberculous myco-
bacterial cervicofacial lymphadenitis in children: a multicenter,
randomized, controlled trial. Clin Infect Dis 2007; 44: 1057–1064.
18. Wolinsky E. Mycobacterial lymphadenitis in children: a prospective
study of 105 nontuberculous cases with long-term follow-up. Clin
Infect Dis 1995; 20: 954–963.
19. Piersimoni C, Goteri G, Nista D et al. Mycobacterium lentiﬂavum as an
emerging causative agent of cervical lymphadenitis. J Clin Microbiol
2004; 42: 3894–3897.
20. Huber J, Richter E, Binder L et al. Mycobacterium bohemicum and cer-
vical lymphadenitis in children. Emerg Infect Dis 2008; 14: 1158–1159.
21. Phillips P, Bonner S, Getaric N et al. Nontuberculous mycobacterial
immune reconstitution syndrome in HIV-infected patients: spectrum
of disease and long-term follow-up. Clin Infect Dis 2005; 41: 1483–
1497.
22. Blackwell V. Mycobacterium marinum infections. Curr Opin Infect Dis
1999; 12: 181–184.
23. Walsh DS, Portaels F, Meyers WM. Buruli ulcer (Mycobacterium ulcer-
ans infection). Trans R Soc Trop Med Hyg 2008; 102: 969–978.
24. Saubolle MA, Kiehn TE, White MH et al. Mycobacterium haemophilum:
microbiology and expanding clinical and geographic spectra of disease
in humans. Clin Microbiol Rev 1996; 9: 435–447.
25. Brown BA, Springer B, Steingrube VA et al. Mycobacterium wolinskyi
sp. nov. and Mycobacterium goodii sp. nov. rapidly growing species
related to Mycobacterium smegmatis and associated with human
wound infections: a cooperative study from the International Work-
ing Group on Mycobacterial Taxonomy. Int J Syst Bacteriol 1999; 49:
1493–1511.
26. Viana-Niero C, Lima KV, Lopes ML et al. Molecular characterization
of Mycobacterium massiliense and Mycobacterium bolletii in outbreaks of
infections after laparoscopic surgeries and cosmetic procedures. J Clin
Microbiol 2008; 46: 850–855.
27. Danesh-Clough T, Theis JC, van der Linden A. Mycobacterium xenopi
infection of the spine: a case report and literature review. Spine
2000; 25: 626–628.
28. Greene JB, Sidhu GS, Leasin S et al. Mycobacterium avium–intracellulare:
a cause of disseminated life threatening infection in homosexuals and
drug abusers. Ann Intern Med 1982; 97: 539–546.
29. Peche`re M, Opravil M, Wald A et al. Clinical and epidemiological fea-
tures of infection with Mycobacterium genavense. Arch Intern Med
1995; 155: 400–404.
30. Le´vy-Fre´bault V, Pangon B, Bure´ A et al. Mycobacterium simiae and
Mycobacterium avium–M. intracellulare mixed infection in acquired
immune deﬁciency syndrome. J Clin Microbiol 1987; 25: 154–157.
31. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium com-
plex in patients with HIV infection in the era of highly active antiret-
roviral therapy. Lancet Infect Dis 2004; 4: 557–565.
32. Skogberg K, Ruutu P, Tukiainen P et al. Nontuberculous mycobacte-
rial infection in HIV-negative patients receiving immunosuppressive
therapy. Eur J Clin Microbiol Infect Dis 1995; 14: 755–763.
33. Vejlgaard TB, Haahr V, Peterslund NA. Atypical mycobacteria. Dis-
seminated infections in patients with hematologic diseases. Ugeskr
Laeg 1997; 159: 5362–5367.
34. Tortoli E, Mantella A, Mariottini A et al. Successfully treated spondy-
lodiscitis due to a previously unreported mycobacterium. J Med
Microbiol 2006; 55: 119–121.
35. Otaki Y, Nakanishi T, Nanami M et al. A rare combination of sites of
involvement by Mycobacterium intracellulare in a hemodialysis patient:
multifocal synovitis, spondylitis, and multiple skin lesions. Nephron
2002; 92: 730–734.
36. Okubo H, Iwamoto M, Yoshio T et al. Rapidly aggravated Mycobacte-
rium avium infection in a patient with rheumatoid arthritis treated
with inﬂiximab. Mod Rheumatol 2005; 15: 62–64.
37. Holland SM, Eisenstein E, Kuhns DB et al. Treatment of refractory
disseminated nontuberculous myconacterial infection with inter-
feron-gamma. A preliminary report. New Engl J Med 1994; 330:
1348–1355.
910 Clinical Microbiology and Infection, Volume 15 Number 10, October 2009 CMI
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 906–910
